FDA Expands Tecelera Approval to Include Patients as Young as 12 With Advanced Synovial Sarcoma

The Food and Drug Administration (FDA) has granted full approval to Tecelera (afamitresgene autoleucel) and expanded its use to include eligible patients ages 12 and older with unresectable or metastatic synovial sarcoma whose disease has previously been treated with chemotherapy.

The approval offers a new treatment option for adolescents and adults with the rare soft tissue cancer, particularly those whose disease has progressed despite standard treatment.

Tecelera made history in 2024 when it became the first engineered T-cell therapy approved by the FDA for a solid tumor. Previously authorized for adults through the agency's accelerated approval pathway, the treatment has now received full approval and can be used in eligible patients as young as 12 years old.

"Patients with advanced synovial sarcoma often face limited treatment options once chemotherapy stops working," according to information released by US WorldMeds, the manufacturer of Tecelera. The expanded approval may help address an unmet need for younger patients facing the disease.

What Is TECELRA?

Tecelera is a personalized cell therapy made from a patient's own immune cells. Doctors collect a patient's white blood cells and genetically modify them in a laboratory to recognize and attack cancer cells that express a protein called MAGE-A4.

Not every patient with synovial sarcoma is eligible for the treatment. Patients must undergo testing to determine whether their cancer expresses MAGE-A4 and whether they have a specific human leukocyte antigen (HLA) type required for the therapy to work.

What Did the Clinical Trial Show?

The FDA's decision was based on results from the SPEARHEAD-1 clinical trial, which included 137 patients with advanced synovial sarcoma.

Researchers reported that 43.8% of patients experienced a response to treatment, meaning their tumors shrank following therapy. Complete responses, in which no detectable cancer remained, were seen in 3.6% of patients.

Among patients who responded, the median duration of response was 5.3 months. Notably, nearly one-third of responders (31.9%) maintained their response for two years or longer.

The expansion to younger patients was supported by data showing that Tecelera exposure in patients ages 12 and older is comparable to that seen in adults. Researchers also determined that the disease behaves similarly in adolescents and adults with unresectable or metastatic synovial sarcoma.

What Patients Should Know

Tecelera is administered at specialized treatment centers and requires careful monitoring. Patients are typically hospitalized around the time of treatment and monitored closely afterward because serious side effects can occur.

The therapy carries a boxed warning for potentially severe or life-threatening side effects. Patients should immediately contact their health care team if they experience symptoms such as fever, chills, difficulty breathing, irregular heartbeat, low blood pressure, severe nausea or vomiting, severe headache or rash.

After receiving Tecelera, patients are monitored daily for at least seven days and are advised to stay near their treatment center for at least two weeks. Patients also should avoid driving or operating heavy machinery for at least two weeks after treatment.

The most common side effects reported with Tecelera include nausea, fatigue, musculoskeletal pain, infection, fever, constipation, vomiting, headache, diarrhea, cough, rapid heart rate, swelling, shortness of breath, rash and low blood cell counts.

For eligible patients and families facing advanced synovial sarcoma, the approval expands access to a first-in-class cell therapy and provides a new treatment option after chemotherapy.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.